In non-small cell lung cancer, MT1DP inhibits NRF2-mediated antioxidant effects through the miR-365a-3p/NRF2 axis, enhancing sensitivity to Erastin (31). This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.